EUCTR2019-000938-20-NL进行中(未招募)1 期
Pharmacokinetic study of minocycline in patients with pulmonary nontuberculous mycobacterial disease - MINO PK in NTM
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- Radboudumc
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- ATS diagnostic criteria for NTM-PD are met, i.e. the patient is symptomatic, has nodules, bronchiectasis or fibro-cavitary lesions seen on (HR)CT scan of the lungs and =2 positive sputum cultures or one positive BAL culture of the same M. avium complex species.
- •- The subject is eligible to start the guideline-recommended rifampicin-based regimen according to the treating physician.
- •- At least one of the positive cultures must be done in the last 4 months before inclusion.
- •- Age = 18 years.
- •- Signed and dated patient informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 7
排除标准
- •- A relevant medical history or current condition that might interfere with drug absorption, distribution, metabolism or excretion (i.e. chronic gastro-intestinal disease, renal or hepatic disease).
- •- Diagnosed with cystic fibrosis (as this may affect the pharmacokinetics of drugs).
- •- Pregnant or breastfeeding (contra-indications for minocycline) or inadequate contraceptive measures (in view of the administration of rifampicin which interacts with oral contraceptive drugs).
- •- Use of drugs that cause a relevant drug interaction with minocycline, i.e. oral magnesium, bismuth, aluminium, calcium, zinc or iron containing formulations (antacid drugs, multivitamin and mineral-containing drugs) and other drugs besides rifampicin that induce metabolic enzymes, including but not limited to barbiturates, carbamazepin and phenytoin. The investigators refer to the ‘Flockhart’table for check of presence of possible inducers (https://drug-interactions.medicine.iu.edu/Main-Table.aspx).
- •- ALAT > 3 times the upper limit of normal (normal <45 U/l).
- •- ASAT > 3 times the upper limit of normal (normal <35 U/l).
- •- An abnormal serum creatinine level (defined as a level that is higher than the upper limit of normal, i.e. >110 umol/l).
- •- Active alcohol abuse.
- •- Hypersensitivity to minocycline or to other tetracycline antibiotics.
研究者
相似试验
招募中
不适用
Pharmacokinetic study of minocycline in patients with nontuberculous mycobacterial diseaseNL-OMON54666Radboud Universitair Medisch Centrum15
进行中(未招募)
1 期
Oral Minocycline for GAGeographic Atrophy Associated with Age-Related Macular DegenerationEUCTR2017-000946-24-GBational Eye Institute45
招募中
2 期
Study of efficacy and safety of minocycline in pleurodesisJPRN-jRCTs061210024Toyooka Shinichi19
进行中(未招募)
1 期
A Pilot Study for the Evaluation of Minocycline in the Treatment of Central Retinal Vein OcclusionsCentral Retinal Vein OcclusionEUCTR2017-001143-12-GBThe National Eye Institute20
进行中(未招募)
1 期
A Pilot Study for the Evaluation of Minocycline in the Treatment of Branch Retinal Vein OcclusionsBranch Retinal Vein OcclusionEUCTR2017-001179-21-GBThe National Eye Institute20
